KalVista Pharmaceuticals, Inc.
KALV
Price:
$16.4
Market Cap:
$828.96M
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, ...[Read more]
Industry
Biotechnology
IPO Date
2015-04-09
Stock Exchange
NASDAQ
Ticker
KALV
PE Ratio
[-4.16]
ROE
[-195.62%]
Current Ratio
[5.37]
Dividend Yield
[0%]
Enterprise Value
[710.80M]
Dividend History
The ROE as of December 2025 (TTM) for KalVista Pharmaceuticals, Inc. (KALV) is -195.62%
According to KalVista Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -195.62%. This represents a change of 193.00% compared to the average of -66.76% of the last 4 quarters.
KalVista Pharmaceuticals, Inc. (KALV) Historical ROE (quarterly & annually)
How has KALV ROE performed in the past?
The mean historical ROE of KalVista Pharmaceuticals, Inc. over the last ten years is -58.13%. The current -195.62% ROE has changed 236.53% with respect to the historical average. Over the past ten years (40 quarters), KALV's ROE was at its highest in in the September 2016 quarter at 0%. The ROE was at its lowest in in the July 2025 quarter at -147.33%.
Average
-58.13%
Median
-49.84%
Minimum
-192.31%
Maximum
-17.30%
KalVista Pharmaceuticals, Inc. (KALV) ROE by Quarter and Year
Discovering the peaks and valleys of KalVista Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 213.69%
Maximum Annual ROE = -17.30%
Minimum Annual Increase = -425.28%
Minimum Annual ROE = -192.31%
| Year | ROE | Change |
|---|---|---|
| 2025 | -192.31% | 213.69% |
| 2024 | -61.30% | 31.88% |
| 2023 | -46.49% | 25.59% |
| 2022 | -37.01% | 113.96% |
| 2021 | -17.30% | -50.24% |
| 2020 | -34.76% | 61.56% |
| 2019 | -21.52% | -62.90% |
| 2018 | -57.99% | -2.34% |
| 2017 | -59.38% | 11.62% |
| 2016 | -53.20% | -425.28% |
KalVista Pharmaceuticals, Inc. (KALV) Average ROE
How has KALV ROE performed in the past?
The current ROE of KalVista Pharmaceuticals, Inc. (KALV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-100.03%
5-year avg
-70.88%
10-year avg
-58.13%
KalVista Pharmaceuticals, Inc. (KALV) ROE vs. Peers
How is KALV’s ROE compared to its peers?
KalVista Pharmaceuticals, Inc.’s ROE is greater than Gossamer Bio, Inc. (-1774.72%), greater than 4D Molecular Therapeutics, Inc. (-47.27%), greater than Prothena Corporation plc (-72.66%), greater than Bicycle Therapeutics plc (-35.54%), less than Omeros Corporation (57.33%), greater than Verastem, Inc. (-9587.28%), less than Rigel Pharmaceuticals, Inc. (204.70%), greater than Olema Pharmaceuticals, Inc. (-41.51%), less than ADC Therapeutics S.A. (82.24%), greater than RAPT Therapeutics, Inc. (-61.81%),
| Company | ROE | Market cap |
|---|---|---|
| -1774.72% | $753.86M | |
| -47.27% | $522.60M | |
| -72.66% | $600.74M | |
| -35.54% | $494.72M | |
| 57.33% | $781.96M | |
| -9587.28% | $641.71M | |
| 204.70% | $845.55M | |
| -41.51% | $1.90B | |
| 82.24% | $409.60M | |
| -61.81% | $570.05M |
Build a custom stock screener for KalVista Pharmaceuticals, Inc. (KALV) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like KalVista Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
KalVista Pharmaceuticals, Inc. (KALV) and other stocks custom spreadsheet templates
The easiest way to analyze a company like KalVista Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is KalVista Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for KalVista Pharmaceuticals, Inc. (KALV)?
What is the highest ROE for KalVista Pharmaceuticals, Inc. (KALV)?
What is the 3-year average ROE for KalVista Pharmaceuticals, Inc. (KALV)?
What is the 5-year average ROE for KalVista Pharmaceuticals, Inc. (KALV)?
How does the current ROE for KalVista Pharmaceuticals, Inc. (KALV) compare to its historical average?